The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

被引：0
|
作者：
Wilson, J. M. [1 ]
Nikooienejad, A. [1 ]
Bowsman, L. M. [1 ]
Schroeder, J. M. [1 ]
Hamlin, D. M. [1 ]
Robins, D. A. [1 ]
Riesmeyer, J. S. [1 ]
Haupt, A. [1 ]
Duffin, K. L. [1 ]
Ruotolo, G. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1161
引用
收藏
页码：S558 / S559
页数：2
相关论文
共 50 条
  • [31] Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
    Dahl, Dominik
    Onishi, Yukiko
    Norwood, Paul
    Huh, Ruth
    Patel, Hiren
    Rodriguez, Angel
    DIABETES, 2021, 70
  • [32] Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes
    Nauck, M. A.
    Frias, J. P.
    Van, J.
    Benson, C. T.
    Bray, R.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S59 - S59
  • [33] DUAL GIP-GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES GLUCOSE CONTROL AND INSULIN SENSITIVITY IN MIXED MEAL TESTS IN PEOPLE WITH TYPE 2 DIABETES
    Mari, A.
    Heise, T.
    Devries, J. H.
    Kiljanski, J.
    Urva, S.
    Li, J.
    Coskun, T.
    Mather, K. J.
    Haupt, A.
    Pratt, E. J.
    Milicevic, Z.
    Thomas, M. K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A178 - A179
  • [34] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [35] Tirzepatide, a dual GIP/GLP-1 receptor agonist, interrupts metabolic adaptation to dietary restriction
    Coskun, T.
    Roell, W. C.
    O'Farrell, L. S.
    Beebe, E. C.
    Regmi, A.
    Emmerson, P. J.
    Milicevic, Z.
    Haupt, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S58 - S59
  • [36] Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D
    Hartman, Mark L.
    Sanyal, Arun
    Loomba, Rohit
    Wilson, Jonathan M.
    Bray, Ross
    Nikooienejad, Amir
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    DIABETES, 2019, 68
  • [37] Weekly dual GIP/GLP-1 receptor agonist tirzepatide monotherapy improved markers of islet cell function and insulin sensitivity in people with type 2 diabetes (SURPASS-1)
    Lee, C. J.
    Thieu, V. T.
    Mao, H.
    Thomas, M. K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 246
  • [38] Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
    Ma, Zijun
    Jin, Kaiqin
    Yue, Mengmeng
    Chen, Xin
    Chen, Jun
    JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [39] Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
    Rangraze, Imran Rashid
    Khan, Shehla
    Wali, Adil Farooq
    Menezes, Godfred
    Goud, Manjunatha
    Jabran, Muhammad
    CURRENT DRUG SAFETY, 2024,
  • [40] The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    Bastyr, Edward J., III
    Vignati, Louis
    Tschoep, Matthias H.
    Schmitt, Christophe
    Owen, Klara
    Christensen, Rune Haubo
    DiMarchi, Richard D.
    CELL METABOLISM, 2017, 26 (02) : 343 - +
12345